OpGen, Inc. is a precision medicine company dedicated to developing and commercializing advanced molecular microbiology solutions for both U.S. and international markets. Its comprehensive product suite includes the Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test designed to pinpoint various bacterial nucleic acids and genetic markers of antimicrobial resistance (AMR) from bacterial colonies sourced from diverse specimen types. The company also offers Curetis CE-IVD-marked polymerase chain reaction (PCR)-based test kits for SARS-CoV-2 detection. Beyond diagnostics, OpGen provides sophisticated platforms like the ARES Technology Platform. This platform features the ARES reference database, which leverages next-generation sequencing technology and artificial intelligence-powered bioinformatics to predict antibiotic response for antimicrobial resistance. Another core offering is the Unyvero Platform, an automated, sample-to-answer molecular diagnostics system. It seamlessly integrates automated sample preparation, analysis, and identification of disease-relevant pathogens and their associated antibiotic resistance markers. Fundamentally, OpGen harnesses molecular diagnostics and informatics to actively combat infectious diseases. The company empowers clinicians by providing crucial insights into life-threatening infections, thereby enhancing patient outcomes and significantly slowing the spread of infections caused by multidrug-resistant microorganisms. In a notable collaboration, OpGen is partnered with the New York State Department of Health and ILÚM Health Solutions, LLC, to establish a research program. This initiative focuses on the detection, tracking, and effective management of antimicrobial-resistant infections within healthcare institutions. Established in 2001, OpGen, Inc. maintains its corporate headquarters in Rockville, Maryland.